Dermal Integration Sleeve to Reduce Exit Site Infections.
Dermal Integration Sleeve to Reduce Exit Site Infections.
批准号:
7926373
负责人:
Andrew Marshall
金额:
$19.98万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-07-20 至 2011-06-30
关键词:
AddressAnimal ModelBacteriaBacterial InfectionsBiocompatibleBiocompatible MaterialsBlood CirculationCathetersChemistryDermalDevelopmentDevicesDoctor of PhilosophyDoseEffectivenessEngineeringFamily suidaeFeasibility StudiesHealedHealthcareHumanImplantInfectionInflammationMarshalMeasurementMeasuresMedical DeviceMedicareMethodsModelingMonitorNatural regenerationNosocomial InfectionsPathway interactionsPatientsPhasePlant RootsRiskSiliconesSimulateSiteSkinSkin TemperatureStaphylococcus aureusStructureSurfaceTechniquesTemperatureTestingThermographyTimeTissuesTongueTubeWorkacronymsantimicrobial drugbacterial resistancecommercializationcosthealingimprovedmicrobialmigrationmortalityolder patientpressureprototypepublic health relevanceresearch clinical testingresearch studyscaffoldsealwound
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The longer-term objective of this project is to develop cuffs that will greatly improve tissue integration and sealing to percutaneous devices at their skin exit sites. Improved sealing restores the natural skin barrier and can remove a major path for bacterial infection. In Phase I we intend to build from earlier work in a porcine model showing reduced inflammation and well-integrated dermal tissue with the engineered porous biomaterial central to this proposal and to develop more extensive and quantitative results in support of eventual clinical testing.
Catheters and other percutaneous devices are used in multiple treatment situations, often over long time periods. Infections are an ever present issue; some hundreds of thousands occur each year with a mortality rate exceeding 30,000 patients in the US alone. A significant fraction of these infections occur via the skin barrier breach, providing a microbial migration path along the device outer surface. Present approaches to this issue rely on releasing antimicrobial agents from the device surface or from subcutaneously applied cuffs. These reduce short term infections but do not provide any seal to restore the natural skin barrier for longer term effectiveness. Concern over extended use of agents provoking "superbug" strains, rising pressure from Medicare and others to reduce nosocomial infections, and increasing device use, especially with older patients, make improved approaches essential. With an estimated cost per infection of $25 - $50k, the present situation represents a $6B annual cost to US healthcare. Sphere Templated Angiogenic Regeneration (STAR) 3D scaffolds are engineered biomaterials with tightly controlled pore sizing (~35¿m). Previous work has shown that when formed and applied as exit site cuffs; these scaffolds strongly integrate with dermal tissue and control epidermal tongue permigration. The resulting interface forms a tight seal between the percutaneous device and the surrounding tissue and addresses the root causes of exit site vulnerability - marsupialization, permigration, and microtrauma. The STAR effects are primarily due to pore sizing and largely independent of material or surface chemistry. This allows recognized biocompatible substrate materials to be used, providing an easier commercialization path.
PUBLIC HEALTH RELEVANCE: Use of percutaneous medical devices is associated with a significant risk of infection. A major pathway for bacteria is provided by non healing skin exit sites. Present approaches to this problem are only short term effective and do not address the root causes. New developments in porous biomaterials and methods of using these to form device cuffs that will integrate and seal the exit site offer potential for reduced infection rates.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Infection and Thrombosis Resistant Needle-Free Hemodialysis Access Port and Graft Using STAR Biomaterials
-
批准号:9251877
-
项目类别:
-
资助金额:$14.24万
-
财政年份:2015
-
负责人:Andrew Marshall
-
依托单位:
Product and Regulatory Development of a Needle-Free Hemodialysis Access Port
-
批准号:9752212
-
项目类别:
-
资助金额:$99.86万
-
财政年份:2015
-
负责人:Andrew Marshall
-
依托单位:
Product and Regulatory Development of a Needle-Free Hemodialysis Access Port
-
批准号:10016390
-
项目类别:
-
资助金额:$99.78万
-
财政年份:2015
-
负责人:Andrew Marshall
-
依托单位:
Product and Regulatory Development of a Needle-Free Hemodialysis Access Port
-
批准号:10202696
-
项目类别:
-
资助金额:$98.45万
-
财政年份:2015
-
负责人:Andrew Marshall
-
依托单位:
Infection and Thrombosis Resistant Needle-Free Hemodialysis Access Port and Graft Using STAR Biomaterials
-
批准号:9031805
-
项目类别:
-
资助金额:$59.57万
-
财政年份:2015
-
负责人:Andrew Marshall
-
依托单位:
Biointegrating Dialysis Access Graft with Self Stabilizing Flow
-
批准号:9142347
-
项目类别:
-
资助金额:$63.36万
-
财政年份:2014
-
负责人:Andrew Marshall
-
依托单位:
Vascular Grafts for Needle Free Dialysis Access Devices.
-
批准号:8781609
-
项目类别:
-
资助金额:$22.45万
-
财政年份:2014
-
负责人:Andrew Marshall
-
依托单位:
Biointegrating Dialysis Access Graft with Self Stabilizing Flow
-
批准号:9319741
-
项目类别:
-
资助金额:$28.07万
-
财政年份:2014
-
负责人:Andrew Marshall
-
依托单位:
Biointegrating Dialysis Access Graft with Self Stabilizing Flow
-
批准号:9048990
-
项目类别:
-
资助金额:$58.11万
-
财政年份:2014
-
负责人:Andrew Marshall
-
依托单位:
Fibrosis-Resistant Bleb-Free Gaucoma Implant
-
批准号:8713342
-
项目类别:
-
资助金额:$20.65万
-
财政年份:2014
-
负责人:Andrew Marshall
-
依托单位:
Anti-Infective Dermal Integration Sleeves for Needle Free Dialysis Access Devices
-
批准号:8311585
-
项目类别:
-
资助金额:$44.79万
-
财政年份:2010
-
负责人:Andrew Marshall
-
依托单位:
Anti-Infective Dermal Integration Sleeves for Needle Free Dialysis Access Devices
-
批准号:8539633
-
项目类别:
-
资助金额:$46.12万
-
财政年份:2010
-
负责人:Andrew Marshall
-
依托单位:
海外基金